VIRAL COFACTORS IN HIV INFECTION

我们建议研究致病的病毒决定因素。 被人类免疫缺陷病毒(HIV)感染。有丰富的 分子、病毒学和流行病学证据表明病毒 辅因，特别是EB病毒、乙肝病毒 (乙肝病毒)和巨细胞病毒(CMV)可能参与了 艾滋病相关复合体(ARC)与艾滋病的发病机制。我们 因此，计划检查这些病毒与艾滋病毒的关系 感染细胞以确定是否可能存在辅因子关系 活着。 我们计划进行原位杂交和免疫组织化学 对HIV感染者的组织和细胞进行染色 血清阳性，有ARC，有艾滋病，有控制性疾病。我们 目的确定表现出HIV表达的细胞是否也 显示EB病毒、乙肝病毒或巨细胞病毒或边界等细胞的表达。 大量的淋巴组织，骨髓，脑和 外周血淋巴细胞将用联合检测 原位杂交技术检测HIV-RNA和 免疫组织化学染色检测HIV RNA和 免疫组织化学染色检测EB病毒、乙肝病毒或巨细胞病毒 抗原；此外，组织将使用联合检测 原位杂交法检测CMV或HBVRNA和 免疫组织化学染色检测HIV的表达 抗原。从没有机会主义倾向的人身上提取的组织 CMV、乙肝病毒或EB病毒在同一细胞中的感染或表达 邻近表达艾滋病毒的细胞将在体内增加证据 已有的体外证据表明这些病毒可能起作用 作为艾滋病毒感染进程中的辅助因素。 此外，我们还将进行一系列实验来分析 无论是CMV还是EBV都能增强人类免疫缺陷病毒的产生 体外培养。如果体外增强作用被证明，我们将测试 看看这种作用是否能被抑制CMV或 EBV复制。

We propose to investigate the viral determinants of pathogenesis by the human immunodeficiency virus (HIV). There is abundant molecular, virologic, and epidemiologic evidence that viral cofactors, particularly Epstein-Barr virus (EBV), hepatitis B virus (HBV), and cytomegalovirus (CMV), may be involved in the pathogenesis of AIDS related complex (ARC) and AIDS. We therefore plan to examine the relationship of these viruses to HIV infected cells to determine if a cofactor relationship may exist in vivo. We plan to perform in situ hybridization and immunohistochemical staining on tissues and cells from individuals who are HIV seropositive and well, have ARC, have AIDs, and controls. We aim to determine if cells demonstrating expression of HIV also show expression of EBV, HBV, or CMV or border or such cells. Numerous samples of lymphoid tissue, bone marrow, brain, and peripheral blood lymphocytes will be examined using the combined technique of in situ hybridization to detect HIV RNA and immunohistochemical staining to detect HIV RNA and immunohistochemical staining to detect EBV, HBV, or CMV antigen; in addition tissues will be examined using combined in situ hybridization to detect CMV or HBV RNA and immunohistochemical staining to detect expression of HIV antigen. In tissues derived from people without opportunistic infections, expression of CMV, HBV, or EBV in the same cells or cells neighboring those expressing HIV will add in vivo evidence to the already existing in vitro evidence that these viruses may act as cofactors in the progression of HIV infection. In addition, we shall perform a series of experiments to assay whether CMV or EBV can potentiate the production of HIV in vitro. If in vitro potentiation is demonstrated, we shall test to see if this effect can be blocked by agents that inhibit CMV or EBV replication.